We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
DBV Technologies
DBVT
$797M
$71.6M 0.31%
1,461,426
– –
TIL icon
27
Instil Bio
TIL
$48.9M
$69.6M 0.31%
194,685
– –
VERV
28
DELISTED
Verve Therapeutics
VERV
$66.6M 0.29%
1,416,530
– –
VSTM icon
29
Verastem
VSTM
$534M
$66.2M 0.29%
1,790,969
– –
HZNP
30
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$65.6M 0.29%
599,110
– –
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.3B
$64.9M 0.29%
676,975
– –
INSM icon
32
Insmed
INSM
$22.5B
$59.4M 0.26%
2,156,001
– –
IMTX icon
33
Immatics
IMTX
$1.22B
$57.5M 0.25%
4,423,731
+140,793
+3% +$1.79M
ADAP
34
DELISTED
Adaptimmune Therapeutics
ADAP
$50.8M 0.22%
9,830,877
– –
RYTM icon
35
Rhythm Pharmaceuticals
RYTM
$7.39B
$50.5M 0.22%
3,863,239
– –
ZYME icon
36
Zymeworks
ZYME
$1.63B
$49.6M 0.22%
1,708,472
– –
TVTX icon
37
Travere Therapeutics
TVTX
$5.23B
$49.5M 0.22%
2,039,772
+1,852,857
+991% +$34M
BLUE
38
DELISTED
bluebird bio
BLUE
$47.8M 0.21%
192,978
+175,455
+1,001% +$50.2M
TLIS
39
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$47.3M 0.21%
504,989
– –
FMTX
40
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$47M 0.21%
2,024,876
– –
MRUS
41
DELISTED
Merus
MRUS
$44.8M 0.2%
2,037,469
– –
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$2.48B
$40.1M 0.18%
444,444
– –
ALKS icon
43
Alkermes
ALKS
$8.12B
$37.9M 0.17%
1,228,170
– –
FLGT icon
44
Fulgent Genetics
FLGT
$563M
$36.1M 0.16%
401,016
– –
JBIO
45
Jade Biosciences
JBIO
$1.19B
$34.7M 0.15%
47,205
+6,389
+16% +$3.58M
ALGS icon
46
Aligos Therapeutics
ALGS
$26.1M
$32.2M 0.14%
83,056
+18,656
+29% +$7.38M
KNSA icon
47
Kiniksa Pharmaceuticals
KNSA
$6.24B
$31.9M 0.14%
2,799,577
– –
KRYS icon
48
Krystal Biotech
KRYS
$10.7B
$31.7M 0.14%
607,735
– –
NGNE icon
49
Neurogene
NGNE
$663M
$27.6M 0.12%
191,087
– –
SYRE icon
50
Spyre Therapeutics
SYRE
$8.49B
$27.1M 0.12%
136,404
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Baker Bros. Advisors held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Baker Bros. Advisors's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Baker Bros. Advisors fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Baker Bros. Advisors opened 12 new positions and closed 10 in Q3 2021.
  • Baker Bros. Advisors's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.